Investor Overview

Corporate Profile
Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Our regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Our first investigational product candidate, NeoCart®, leverages our platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee. For more information on Histogenics, please visit the company website at www.histogenics.com.
Stock Quote
HSGX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$2.98
Change (%) Stock is Up 0.09 (3.11%)
Volume6,902
Data as of 08/25/16 1:26 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
08/11/16Histogenics Corporation Announces Second Quarter 2016 Financial and Operating Results
- NeoCart® Phase 3 Clinical Trial Remains on Track for Enrollment  Completion by End of Second Quarter of 2017 -  - Increasing Year-End 2016 Enrollment Guidance to 190 to 200 patients -  - Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT - WALTHAM, Mass., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced its financ... 
Printer Friendly Version
07/28/16Histogenics Corporation to Announce Second Quarter 2016 Financial Results on August 11, 2016
WALTHAM, Mass., July 28, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced it will release its financial and operational results for the quarter ended June 30, 2016 on August 11, 2016 before the market opens.  Histogenics’ management will host a conference call on Thursday, August 11, 2016 at 8:30 a.m. EDT.  A question-and-answer session will follow Histog... 
Printer Friendly Version
07/27/16Histogenics Corporation to Present at the Canaccord Genuity Growth Conference
WALTHAM, Mass., July 27, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley, President and Chief Executive Officer of Histogenics, will present at the 36th Annual Growth Conference on Wednesday, August 10, 2016 at 8:00 AM EDT at the InterContinental Boston, Boston MA.  This presentation will be webcast live and may be a... 
Printer Friendly Version
05/12/16Histogenics Corporation Announces First Quarter 2016 Financial and Operating Results
- NeoCart® Phase 3 Clinical Trial Remains on Track for Enrollment Completion by End of Second Quarter of 2017 - - Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT - WALTHAM, Mass., May 12, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced its financial and operational results for the quarter ended March 31, 2016.  “We made s... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Contact Information

Histogenics Corporation
Phone: 781.547.7900
E-mail: InvestorRelations@histogenics.com

Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Histogenics Corp posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.